Targeted Therapies for Eosinophilic Gastrointestinal Disorders
- 29 May 2020
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 34 (4) , 477-493
Abstract
The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinophilic esophagitis (EoE), have unveiled essential pathophysiological mechanisms leading to these disorders, which bear some similarities to those of atopic manifestations and are shared by eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). Novel targeted therapies, some imported from bronchial asthma and atopic dermatitis, are currently being assessed in EoE. The most promising are monoclonal antibodies, including those targeting interleukin (IL)-13 (cendakimab) and IL-4 (dupilumab), with phase 3 trials currently ongoing. The potential of anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) in EGE are also promising. Non-biological therapies for eosinophilic gut disorders, which include preventing the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and chemoattractant receptor expressed on T helper 2 cells (CRTH2) signaling pathways, and other potential targets that deserve investigation in eosinophilic gut disorders, are reviewed.Keywords
This publication has 122 references indexed in Scilit:
- High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disordersJournal of Allergy and Clinical Immunology, 2013
- Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitisAllergy, 2013
- Omeprazole Blocks STAT6 Binding to the Eotaxin-3 Promoter in Eosinophilic Esophagitis CellsPLOS ONE, 2012
- Development of a validated patient-reported symptom metric for pediatric Eosinophilic Esophagitis: qualitative methodsBMC Gastroenterology, 2011
- Eosinophilic Gastrointestinal Disorders (EGID) with Peripheral Eosinophilia: A Retrospective Review at Mayo ClinicDigestive Diseases and Sciences, 2011
- Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disordersClinical and Molecular Allergy, 2011
- Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United StatesJournal of Pediatric Gastroenterology and Nutrition, 2011
- Interleukin‐13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophilsClinical & Experimental Allergy, 2010
- Allergy and eosinophil-associated gastrointestinal disorders (EGID)Current Opinion in Immunology, 2008
- Radiographic manifestations of eosinophilic gastroenteritisAbdominal Radiology, 1995